
A group of Hong Kong-listed biotechnology companies have seen their stock prices surge in the wake of Moderna’s breakthrough cancer vaccine trial, as the Chinese companies push forward with similar vaccine programmes. The companies – from…
View original source — South China Morning Post ↗

